Oramed Pharmaceuticals (ORMP) Non-Current Deffered Revenue (2016 - 2025)

Oramed Pharmaceuticals has reported Non-Current Deffered Revenue for 10 years, with the latest figure at $2.0 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 50.0% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $2.0 million (down 50.0% YoY), and the FY2025 full-year result was $2.0 million, down 50.0% from the prior year.
• Non-Current Deffered Revenue for Q4 2025 stood at $2.0 million, roughly flat from $2.0 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $5.6 million in Q1 2021, with the low at $1.7 million in Q2 2025.
• Historically, Non-Current Deffered Revenue has averaged $3.5 million across 5 years, with a median of $4.0 million in 2022.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue surged 100.0% — and 2025, when it sank 56.9%.
• Oramed Pharmaceuticals' Non-Current Deffered Revenue stood at $3.6 million in 2021, then advanced by 12.04% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then changed by 0.0% to $4.0 million in 2024, then slumped by 50.0% to $2.0 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $1.7 million (Q2 2025), per Business Quant data.